← All candidates
Three insider buys in the last year — $226.6K in all.
9 filings on record.
RLYBRallybio Corp
NasdaqCM · Healthcare · $91.32M
$17.19
+0.17% · Sep 18
Three insider buys in the last year — $226.6K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 3 buys● 1 sell◆ 2 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what RLYB ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$91.32M
Float
2.2M
41% public
Short % float
Pro
Price / profit
2.1
Price / future profit
—
Price / sales
141.4
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
ADAR1 Capital Management, LLC
Bought $139.8K on May 19 — 10,000 sh @ $13.98, held indirect, 1.1% of their stake.
No completed positions to measure
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
4 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
1 more transaction on Pro →Context
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$1.46 act−$0.26
Q4 '25−$1.52 act−$0.28
Q3 '25$2.88 act+$4.44
Q2 '25−$1.76 act+$0.20
Coverage
Rallybio to acquire Candid TherapeuticsPharmaceutical Technology · 03-03Candid, in a reverse merger with RallyBio, to go publicBioPharma Dive · 03-02Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 AdvancesInsider Monkey · 09-21Rallybio First Half 2025 Earnings: US$0.43 loss per share (vs US$0.83 loss in 1H 2024)Simply Wall St. · 08-09
The file stays open
9 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice